Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
Ophatuma MAB: A Drug That Nobody Uses for Anything?
Ophatuma MAB has been studied and they added it to the Hyper-C VAD regimen. They compared it to retuxin, their historical control with the retuxin. And so it brings up the question of, should we be using Ophatuma mab instead of retuxin? And will that improve outcome? So what they found was that the event-free survival was nearly doubled when you added Ophatumasmba. But again, I wish the study would have answered that question, but they didn't design it appropriately.
Transcript
Play full episode
